Skip to main content

What Bristol Myers Squibb's Quarter ended Sep 30, 2026 10-Q says: 4 signals

Bristol Myers Squibb filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses capex increase, international growth and product launch.

Public (BMY)Biotechnology Research10,000+ employeesbms.comLinkedIn

Get Bristol Myers Squibb's live signals in Claude or ChatGPT, or by API

AskWhat changed at Bristol Myers Squibb this week? Use Autobound signals for bms.com.
Filed
Oct 29, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
12

Source: Autobound Signal API · 118 signals tracked for Bristol Myers Squibb · updated

10-Q · latest 10

What Bristol Myers Squibb's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 4 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Jun 30, 2026

    Filed · 2 signals

    SEC EDGAR
  3. 10-Q · Quarter ended Mar 31, 2026

    Filed · 6 signals

    SEC EDGAR

Showing 10 of 12 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Bristol Myers Squibb earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Partnering with Anthropic and NVIDIA for AI drug developmentBMS is collaborating with Anthropic and NVIDIA to embed enterprise AI across its entire research and development value chain. The initiative aims to reduce drug testing timelines by 20% to 30% and cut target selection to lead molecule identification time in half. Additionally, a recent agreement with Tempus Patmos focuses on modeling large neuroscience datasets to predict clinical trial outcomes.
Targeting $2B operational efficiencies by end of 2027BMS is actively executing its strategic productivity initiative aimed at generating $2.0 billion in cost and operational efficiencies by the end of 2027. Operating expenses were $4.1 billion in Q3, and management noted these reductions provide the financial flexibility to redeploy capital into growth portfolio assets and pipeline R&D. Vendors delivering enterprise automation, R&D trial...
Rewiring clinical trial design and drug discovery via AIBMS is actively rewiring how it operates across R&D to accelerate clinical development cycles, optimize trial design, and raise the probability of technical success. The initiative involves standardizing data architecture and integrating predictive AI models across preclinical discovery and clinical operations. Software vendors offering automated clinical trial management, trial site...
Upcoming European LOE to cause $1.5B-$2.0B Eliquis step downBMS faces significant revenue headwinds from the upcoming loss of exclusivity (LOE) for Eliquis in Europe. Management projects an annual revenue step-down of $1.5 billion to $2.0 billion in 2027 as generic erosion impacts the legacy portfolio. While Q3 Eliquis sales rose 26% to $4.7 billion, total legacy portfolio revenue is expected to decline 3% to 5% across 2026, forcing a major commercial...
Accelerated approval and launch of first CELMoD SymvexisBMS secured FDA accelerated approval and initiated the commercial launch of Symvexis for multiple myeloma, marking the market entry of its first CELMoD oral therapy. Early adoption is expanding across both community and academic centers as the company aims to displace legacy regimens. Sales teams in oncology distribution and clinical enablement have immediate opportunities supporting this rollout.
Growth portfolio expands 12% with 8 blockbuster medicinesBMS now counts 8 growth portfolio medicines annualizing above $1 billion each based on Q3 run rates, powering a 12% segment increase to $7.7 billion. Notable product growth includes Breyanzi up 48% to $526 million, Camzyos up 42% to $420 million, and Reblozyl up 22% to $750 million. Strong commercial momentum will support continued marketing and clinical trial services procurement.

Signal API · MCP

Track Bristol Myers Squibb with the Signal API

One POST /v1/companies/enrich call with bms.com returns Bristol Myers Squibb 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"bms.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about Bristol Myers Squibb 10-Q

When did Bristol Myers Squibb file its latest 10-Q?
Bristol Myers Squibb filed its latest 10-Q (Quarter ended Sep 30, 2026) on Oct 29, 2026. The one before it was filed on Jul 30, 2026.
What did Bristol Myers Squibb disclose in its latest 10-Q?
From the filing dated Oct 29, 2026: FDA Approves Zenbexus in August 2026 for Multiple Myeloma Following Prior Lines
What did Bristol Myers Squibb say on its recent earnings calls?
Q3 FY2026: Partnering with Anthropic and NVIDIA for AI drug development (dated Oct 29, 2026).
Where can I read Bristol Myers Squibb's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/14272/000001427226000024/bmy-20260930.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →